
MELLODDY
Belgium · Consortium
Machine Learning Ledger Orchestration for Drug DiscoverY; a consortium of 10 pharma companies training models on federated data.
A biotech company that uses federated learning to train AI models on distributed patient data without the data leaving hospitals.
Provides the 'Rhino Health Platform', a federated computing platform designed to allow healthcare AI developers to access diverse datasets across hospitals.
Offers a zero-trust collaboration platform for healthcare AI, utilizing secure enclaves to compute on sensitive clinical data.
Provides a platform for secure data collaboration using Homomorphic Encryption.
Offers a privacy suite that allows algorithms to run on encrypted data without decryption, using MPC and other techniques.
Data privacy software company enabling organizations to use sensitive data safely for analytics.
Develops silicon spin qubits using advanced 300mm wafer manufacturing processes.
Developing foundation models for robotics (Project GR00T) and vision-language models like VILA.
Healthcare institutions have long struggled with a fundamental tension: the need to share data for research and quality improvement versus strict privacy regulations and patient confidentiality requirements. Traditional approaches to multi-institutional research require centralising sensitive patient records, creating significant security vulnerabilities and regulatory hurdles under frameworks like HIPAA and GDPR. Privacy-preserving health analytics represents a paradigm shift in how medical data can be leveraged for insights without compromising individual privacy. At its core, this approach employs several complementary techniques. Federated learning allows multiple hospitals to collaboratively train machine learning models by keeping raw patient data on local servers while only sharing model updates or aggregated parameters. Differential privacy adds mathematical noise to datasets or query results, ensuring that no individual patient's information can be reverse-engineered from published statistics. Secure multi-party computation enables institutions to jointly analyse encrypted data without any party seeing the others' unencrypted records. Homomorphic encryption takes this further, allowing computations to be performed directly on encrypted data, with results that remain valid when decrypted. Together, these techniques create architectures where the data never leaves its origin point, yet collective insights emerge from the distributed network.
The healthcare industry faces mounting pressure to improve outcomes while managing costs, yet data silos between institutions have historically prevented the kind of large-scale analysis needed to identify best practices and rare disease patterns. Privacy-preserving analytics directly addresses this fragmentation by enabling cross-institutional collaboration without the legal complexity and security risks of traditional data sharing agreements. Research suggests these methods can unlock insights from datasets spanning hundreds of hospitals, revealing treatment effectiveness patterns and diagnostic accuracy benchmarks that would be invisible within any single institution's walls. For rare diseases, where individual hospitals may see only a handful of cases annually, federated approaches can effectively create virtual cohorts large enough for meaningful statistical analysis. This technology also reduces the compliance burden on healthcare organisations, as patient data remaining on local servers simplifies adherence to data sovereignty requirements and institutional review board protocols. Early deployments indicate that privacy-preserving methods can achieve model performance comparable to centralised approaches while dramatically reducing the time and cost associated with data use agreements and de-identification processes.
Several academic medical centres and health system consortia have begun piloting federated learning platforms for applications ranging from radiology image analysis to predicting patient deterioration and optimising sepsis treatment protocols. Industry analysts note growing interest from pharmaceutical companies seeking to conduct real-world evidence studies across diverse patient populations without the traditional delays of data acquisition. The technology is particularly promising for continuous quality improvement initiatives, where hospitals can benchmark their performance against peers without exposing proprietary practices or sensitive patient information. As healthcare systems increasingly recognise data as a strategic asset, privacy-preserving analytics offers a path forward that balances innovation with protection. The convergence of these techniques with emerging standards for health data interoperability suggests a future where multi-institutional research becomes routine rather than exceptional, accelerating medical discovery while maintaining the trust that is fundamental to the patient-provider relationship. This approach represents not merely a technical solution but a necessary evolution in how healthcare organisations collaborate in an era of both big data opportunity and heightened privacy awareness.